NexGel doubles revenue, widens margins but cash low; going-concern flagged

NexGel, Inc. (NASDAQ: NXGL) - Quick read on what's happening inside

Snapshot: strong top-line growth driven by branded consumer products and the CGN JV, meaningful margin improvement, but the company remains unprofitable, cash is low, and management flags a going-concern risk. The company closed post-period financings and a commercial partnership that reduce-but do not eliminate-near-term liquidity pressure.

Key facts & figures

- Revenues (Q2 2025): $2,884,000 vs Q2 2024: $1,440,000 (up 100.3%).

- Revenues (6 months 2025): $5,690,000 vs 6 months 2024: $2,706,000 (up 110.3%).

- Gross profit (Q2 2025): $1,258,000; gross margin Q2 2025: 43.6% vs 20.3% in Q2 2024.

- Gross profit (6 months 2025): $2,446,000; gross margin 43.0% vs 19.2% in 6 months 2024.

- Loss from operations (Q2 2025): $(636,000); six months: $(1,413,000).

- Net loss attributable to NexGel stockholders (Q2 2025): $(665,000); six months: $(1,377,000).

- Net loss per share, basic (six months 2025): $(0.18) (basic); weighted average shares (six months): 7,649,878.

- Cash at June 30, 2025: $725,000 (beginning of period: $1,807,000). Net cash used in operating activities (six months): $(807,000).

- Total assets: $9,711,000; total liabilities: $4,656,000; total stockholders' equity: $5,055,000 (June 30, 2025).

- Working capital at June 30, 2025: $1,766,000 (down from $2,644,000 at 12/31/24).

What's working (positives)

- Branded consumer products are the growth engine: Q2 branded revenue $1,884,000 vs $968,000 a year earlier; six months branded $3,666,000 vs $1,585,000.

- Gross margins expanded dramatically (20% → ~43%) as mix shifted toward higher-margin branded sales.

- CGN JV contributed positively: Q2 CGN operating income $75,000; six months $170,000 - the JV is producing incremental profit.

- Warrant liability revaluation moved favorably (warrant fair value fell from $118k at 12/31/24 to $14k at 6/30/25), producing non‑operating income.

- Post-period liquidity events: July 14, 2025 partnership with STADA included a $1 million non‑dilutive advance; July/August 2025 financing raised ~ $950,000 gross (413,043 shares at $2.30 plus warrants) and an additional small private placement of $105,000.

Primary concerns (negatives)

- Company remains loss-making: six‑month net loss $1.318M (consolidated) and net cash used in operations $807k - losses expected in near term per management.

- Cash balance is low ($725k at 6/30/25), creating substantial doubt about going concern (management discloses that explicitly).

- SG&A has risen sharply to support branded growth: advertising/marketing + Amazon fees were $621k in Q2 and $1,263k for six months - a big ongoing expense item.

- Customer concentration and receivable risk: for six months 2025 one customer ≈10% of revenue; accounts receivable concentration includes a customer at 35% of total AR as of 6/30/25.

- Material weaknesses in internal controls noted (journal entry approvals, access controls, reconciliation issues); remediation targeted by Dec 31, 2025 - governance risk until fixed.

- Contingent/liability items and acquisition costs: payment of contingent consideration ($178k) and acquisitions (Kenkoderm, Silly George) increase cash strain and create integration risk; intangible assets include $600k indefinite-lived trademark from Silly George.

Operational highlights / segment details

- Revenue mix (Q2 2025): Contract manufacturing $863k; Custom & white label $27k; Consumer branded $1,884k; Other $110k.

- Inventory $1,821,000 with no reserve recorded as of 6/30/25 (management states no reserve required currently).

- Capital spending low in the period ($20k) vs prior year; depreciation & amortization increased (six months D&A $225k).

Liquidity & capital structure

- Notes payable (total principal and accrued schedule) - total debt schedule shows principal amounts due (total reported debt schedule amounts: $638k with current portion $99k; long-term $539k).

- Financing leases present (financing lease PV $337k) and operating lease PV $1,680k (weighted avg remaining term 5.9 years).

- Share dilution: outstanding common shares 7,654,537 as of Aug 12, 2025 and reserved shares include 4,765,205 warrants and 879,111 for awards.

What to watch next (near-term catalysts & risks)

- Execution of STADA partnership product launches and use of the $1M advance to drive European sales.

- Impact of July/August 2025 equity raises on runway - proceeds should ease immediate liquidity pressure but shareholder dilution and warrant overhang remain.

- Progress on internal control remediation (target date Dec 31, 2025) - necessary for audit confidence and investor trust.

- Customer concentration: retention/loss of top customers would materially affect cash and revenue.

- Legal: pending declaratory judgment vs Kiss Nail Products over patent claims related to Silly George eyelash products - an adverse outcome could remove products from Amazon and harm revenue.

Bottom line: NexGel is executing a consumer-brand growth strategy that is delivering fast revenue and margin improvement, but the company still loses money, has a thin cash balance, and reports control weaknesses and concentrated customer risk. Recent partnership and financing after the quarter reduce immediate liquidity pressure but execution risk (sales, integration, legal, controls) remains high.